Taltirelin
ATLPC0035861
(4S)-1-methyl-2,6-dioxohexahydropyrimidine-4-carbonyl-L-His-L-Pro-NH2
- Length46 aa
- Measurements4
- Endpoints2
- Domains1/5
- Products1
- No matrix stability evidence
- No clearance evidence
- Product-level review pending
- No sequence liability cues
Open the matching evidence section below
Sequence & molecular identity
1 formsReviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.
Sequence & peptidoform
A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.
Identity summarySpecific molecular form represented
- Identity status
- Specific molecular form represented
- Residues
- 46
- Peptidoform features
- 42
- Documented molecular forms
- 1
- Representations
- 2
Documented molecular forms1 form linked to this peptide identity
| Form | Topology | Modifications | Connections | Representations | Measurements | |
|---|---|---|---|---|---|---|
| ATLPF0039002 | — | 4 | — | 1 | 4 |
Residue view
Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.
Features are shown only when a reported notation or topology record supports them.
Reported token 1 is not one of the 20 standard residue symbols in this display.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token 2,6 is not one of the 20 standard residue symbols in this display.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token o is not one of the 20 standard residue symbols in this display.
Reported token x is not one of the 20 standard residue symbols in this display.
Reported token o is not one of the 20 standard residue symbols in this display.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token x is not one of the 20 standard residue symbols in this display.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token o is not one of the 20 standard residue symbols in this display.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token 4 is not one of the 20 standard residue symbols in this display.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token b is not one of the 20 standard residue symbols in this display.
Reported token o is not one of the 20 standard residue symbols in this display.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token NH2 is not one of the 20 standard residue symbols in this display.
Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.
Structure & chemistry
Chemical representationsequence / HELM only
How the current release can interpret this identity chemically.
plain sequence-likeResidue string used for positional interpretation when available.
XMETHYLXDIXXXHEXAHYDRXPYRIMIDINEXCARXXNYLLHLPXPolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
3D structure referencesnone attached
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
Covalent topology & modifications1 signal
| Feature | Positions | Interpretation | Link |
|---|---|---|---|
| Form-level topology | ATLPF0039002 | Open-chain form. Residue-level connection endpoints are shown separately when available. | Not linked |
Physicochemical profile
6 descriptorsComputed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.
These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.
Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.
Computed from the representative peptidoform's chemical structure. Rule-of-5 / beyond-Ro5 framing per Lipinski/Doak.
Computed logP — distinct from the measured logD endpoint.
0 Ro5 violations · MW 405.42 Da
Exposure / Absorption
4 recordsWhat evidence describes systemic exposure or absorption?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Bioavailability2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 18.5 % | Eligible when experimental context matches | radiolabeled disposition study with oral and intravenous dosing · dog · plasma total radioactivity | Result: Reported point value · Molecular form: ATLPF0039002 · Route: oral · Source: Primary reference linked | Reference |
| 2 | 3.9 % | Eligible when experimental context matches | radiolabeled disposition study with oral and intravenous dosing · rat · plasma total radioactivity | Result: Reported point value · Molecular form: ATLPF0039002 · Route: oral · Source: Primary reference linked | Reference |
Tmax2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 10800 seconds | Eligible when experimental context matches | human · plasma | Result: Reported point value · Molecular form: ATLPF0039002 · Route: oral · Source: Primary reference linked | Reference |
| 2 | 10800 seconds | Eligible when experimental context matches | human · plasma | Result: Reported point value · Molecular form: ATLPF0039002 · Route: oral · Source: Primary reference linked | Reference |
Evidence landscape
4 recordsCross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.
A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.
Top evidence-bearing endpoint questions.
Broad context buckets, useful before comparing values.
Reference-link availability for measurement-level audit.
Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.
| # | ADMET domain | Endpoint | Reported value | Result type | Analysis use | Assay / model | Condition | Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | Exposure / Absorption Exposure | Time To Max Concentration | 10,800 seconds | Reported point value | Eligible when experimental context matches | human · plasma | Route: oral | Reference Primary reference linked |
| 2 | Exposure / Absorption Exposure | Time To Max Concentration | 10,800 seconds | Reported point value | Eligible when experimental context matches | human · plasma | Route: oral | Reference Primary reference linked |
| 3 | Exposure / Absorption Exposure | Bioavailability | 3.9 % | Reported point value | Eligible when experimental context matches | radiolabeled disposition study with oral and intravenous dosing · rat · plasma total radioactivity | Route: oral | Reference Primary reference linked |
| 4 | Exposure / Absorption Exposure | Bioavailability | 18.5 % | Reported point value | Eligible when experimental context matches | radiolabeled disposition study with oral and intravenous dosing · dog · plasma total radioactivity | Route: oral | Reference Primary reference linked |
Product context
1 productsProduct-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.
Summary1 linked product
- Linked products
- 1
- Label context
- None
- Clinical trials
- 1
- Safety label cues
- None
Linked products1 shown
Taltirelin
Identity & reference map
3 sourcesReference-level support for checking reported names, sequence notation, and peptide identity agreement.
Summary2 reference groups
- Identity type
- reported modified sequence
- Reported notation
- 0
- Reference groups
- 2
- Measurements
- 4
- ATL peptide ID
- ATLPC0035861
Identity concordance
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.
No source-specific sequence notation has been captured in the current identity references.
(4S)-1-methyl-2,6-dioxohexahydropyrimidine-4-carbonyl-L-His-L-Pro-NH2
Reference map2 reference groups
Data access & reproducibility
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Record scopePublic release
- ATL peptide ID
- ATLPC0035861
- Identity type
- reported modified sequence
- ADMET endpoints
- 2
- Evidence records
- 4
- Reference groups
- 2
- Release view
- Public release
Data access
Structured peptide profile
JSONPeptide-specific profile used by this page, including identity and evidence context.
Peptide catalogue
TSVComplete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.
Measurement catalogue
TSVComplete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.
Programmatic access
The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0035861' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'